Published in Br Med J on March 08, 1980
Plasma fibrinogen--a major coronary risk factor. J R Coll Gen Pract (1985) 1.75
Blood rheology. J Clin Pathol (1980) 1.06
Thrombotic vascular risk factors in inflammatory bowel disease. Gut (1996) 1.00
Haemostatic function in myocardial infarction. Br Heart J (1986) 0.92
Assessing methods--descriptive statistics and graphs. Br Med J (Clin Res Ed) (1981) 0.86
Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J (1985) 0.86
Ischaemic heart disease: association with haematocrit in the British Regional Heart Study. J Epidemiol Community Health (1994) 0.85
Haemostatic markers are associated with measures of vascular disease in adults with hypertension. J Hum Hypertens (2009) 0.82
Thrombosis and ischaemic heart disease. Br Heart J (1985) 0.81
Genetic and environmental sources of fibrinogen variability in Israeli families: the Kibbutzim Family Study. Am J Hum Genet (1995) 0.80
Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol (1995) 0.79
Lipid apheresis: oxidative stress, rheology, and vasodilatation. Clin Res Cardiol Suppl (2012) 0.79
Haemorheology in patients with branch retinal vein occlusion with and without risk factors. Graefes Arch Clin Exp Ophthalmol (1996) 0.76
Compensatory Enlargement of Ossabaw Miniature Swine Coronary Arteries in Diffuse Atherosclerosis. Int J Cardiol Heart Vasc (2015) 0.75
Association of hemoglobin with ankle-brachial index in general population. Clinics (Sao Paulo) (2016) 0.75
Primary and secondary blood hyperviscosity syndromes, and syndromes associated with blood hyperviscosity. Drugs (1987) 0.75
[Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol (1957) 12.36
Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. Br Med J (1973) 2.17
Effect of haematocrit on cerebral blood-flow in man. Lancet (1977) 1.80
Influence of blood viscosity on blood flow and the effect of low molecular weight dextran. Br Med J (1971) 1.72
Hemoglobin and the risk of cerebral infarction: the Framingham Study. Stroke (1972) 1.66
Microrheology of erythrocytes, blood viscosity, and the distribution of blood flow in the microcirculation. Int Rev Physiol (1976) 1.29
Blood viscosity, red-cell flexibility, haematocrit, and plasma-fibrinogen in patients with angina. Lancet (1977) 1.29
Elevation of blood viscosity, aggregation of red cells, haematocrit values and fibrinogen levels with cigarette smokers. Med J Aust (1975) 1.26
BLOOD VISCOSITY IN HEALTHY SUBJECTS AND PATIENTS WITH CORONARY HEART DISEASE. Can Med Assoc J (1964) 1.25
Effect of clofibrate on blood viscosity in intermittent claudication. Br Med J (1974) 1.02
A coaxial rhombo-spheroid viscometer: a further development of the cone-in-cone viscometer. Biorheology (1969) 0.93
The role of thrombosis in the etiology of atherosclerosis (a positive one) and in precipitating fatal ischemic heart disease (a negative one). Semin Thromb Hemost (1976) 0.87
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Antithrombotic treatment and atrial fibrillation. BMJ (1992) 5.33
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 4.32
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med (2000) 3.90
Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Q J Med (1977) 3.27
Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke (1999) 2.89
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation (2001) 2.43
Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol (1990) 2.43
Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation (1996) 2.32
Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J (2000) 2.30
Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med (1970) 2.17
Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest (1969) 2.14
Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J (1999) 2.08
Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J (2000) 2.08
Acute exercise and markers of endothelial injury in peripheral arterial disease. Eur J Vasc Endovasc Surg (1997) 2.07
Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia (2011) 2.06
Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol (2001) 1.96
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet (1983) 1.94
Nurse led shared care for patients on the waiting list for coronary artery bypass surgery: a randomised controlled trial. Heart (2001) 1.93
Normal catecholamine production in a patient with a paroxysmally secreting phaeochromocytoma. Ann Clin Biochem (1991) 1.91
Receptor-mediated low density lipoprotein catabolism in man. J Lipid Res (1979) 1.88
Leg-vein thrombosis following myocardial infarction. Lancet (1970) 1.85
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ (1996) 1.85
Idiopathic gangrene in African children. Br Med J (1967) 1.85
Thallium scans in syndrome X. Br Heart J (1992) 1.84
Haemodynamic effects of a new vasodilator drug, felodipine, in healthy subjects. Eur J Clin Pharmacol (1983) 1.73
A general practitioner electrocardiogram service. Scott Med J (1967) 1.69
"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. Br Med J (Clin Res Ed) (1984) 1.69
Effects of physiological concentrations of vasopressin on haemostatic function in man. Clin Sci (Lond) (1985) 1.64
Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1986) 1.64
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
Vascular damage and factor-VIII-related antigen in the rheumatic diseases. Rheumatol Int (1987) 1.62
Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J (1997) 1.60
The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J (1993) 1.60
Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J (1996) 1.59
3 and 12 lead electrocardiogram interpretation by computer. A comparison on 1093 patients. Br Heart J (1971) 1.56
Calculation of predictive odds for possible carriers of heamophilia. Thromb Diath Haemorrh (1975) 1.51
Blood pressure in a Scottish island community. Br Med J (1969) 1.50
Is aspirin safe for patients with heart failure? Br Heart J (1995) 1.49
Thromboprophylaxis--which treatment for which patient? J Bone Joint Surg Br (2000) 1.47
Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care (1989) 1.45
Association of fibrinolytic tests with outcome of acute upper-gastrointestinal-tract bleeding. Lancet (1993) 1.45
Pressure sore prevention for the wheelchair-bound spinal injury patient. Paraplegia (1980) 1.44
Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet (1992) 1.44
Blood pressure and catecholamine responses to 'stress' in normotensive and hypertensive subjects. Cardiovasc Res (1971) 1.43
Improving prospects for employment of the haemophiliac. Br Med J (1980) 1.43
A European view on the North American fifth consensus on antithrombotic therapy. Chest (2000) 1.43
Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost (2007) 1.43
Effect of combined oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity. Lancet (1970) 1.42
The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med (1973) 1.42
A comparison of maximal exercise and dipyridamole thallium-201 planar gated scintigraphy. Eur J Nucl Med (1992) 1.40
Venous and arterial thrombosis in airline passengers. J R Soc Med (1998) 1.40
In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer. Thromb Haemost (1989) 1.39
Finite element modelling of bulk muscular tissue. J Rehabil Res Dev (1998) 1.39
Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J (1995) 1.38
Blood rheology in vitro and in vivo. Baillieres Clin Haematol (1987) 1.36
Dental disease, fibrinogen and white cell count; links with myocardial infarction? Scott Med J (1993) 1.36
Cardiology: the development of a managed clinical network. BMJ (2000) 1.34
Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol (1983) 1.34
Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem (2000) 1.34
Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet (1983) 1.34
The combination of nifedipine and propranolol in the management of patients with angina pectoris. Br J Clin Pharmacol (1981) 1.33
Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest (1984) 1.29
Coagulation, fibrinolysis and platelet function in pre-eclampsia, essential hypertension and placental insufficiency. J Obstet Gynaecol Br Commonw (1971) 1.29
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol (1996) 1.29
The effects of age and cigarette-smoking on blood and plasma viscosity in men. Scott Med J (1980) 1.28
Necrosis, haemorrhage and complement depletion following bites by the spitting cobra (Naja nigricollis). Q J Med (1976) 1.27
How periodontal disease may contribute to cardiovascular disease. Periodontol 2000 (2000) 1.26
Haemostatic changes during dialysis associated with thrombus formation on dialysis membranes. Br Med J (1972) 1.24
Blood rheology in arterial disease. Clin Sci (Lond) (1986) 1.23
Basis of antifibrinolytic therapy. J Clin Pathol Suppl (R Coll Pathol) (1980) 1.22
Fatal retroperitoneal haemorrhage complicating anticoagulant therapy. Postgrad Med J (1979) 1.21
Retrospective cohort mortality study of workers at an aircraft maintenance facility. I. Epidemiological results. Br J Ind Med (1991) 1.20
HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA. Lancet (1984) 1.20
Abnormal platelet function in pre-eclampsia. Br J Obstet Gynaecol (1978) 1.19
Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol (1999) 1.17
The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease. Eur Heart J (1983) 1.17
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol (1997) 1.17
Reduced myocardial reflow and increased coronary vascular resistance following prolonged myocardial ischemia in the dog. Circ Res (1975) 1.17
Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Blood Coagul Fibrinolysis (1995) 1.16
Disordered "fibrinolytic potential" in coronary heart disease. Thromb Res (1977) 1.16
Endotoxemia, disturbance of coagulation, and obstructive jaundice. Am J Surg (1982) 1.15
Diagnosis and treatment of venous thromboembolism by consultants in Scotland. Br Med J (Clin Res Ed) (1983) 1.14
Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg (1977) 1.14
Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet (1993) 1.14
Laboratory diagnosis of congenital coagulation defects. Clin Haematol (1979) 1.13
Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) (1995) 1.13
Free radical pathology in chronic arterial disease. Free Radic Biol Med (1989) 1.13